|
Item 1.01
|
Entry into a Material Definitive Agreement.
|
|
(a)
|
Series D Warrant Amendment
|
On June 3, 2020 (the
“Amendment Execution Date”), the Company entered into that certain Amendment to Series D Warrants to
Purchase Common Stock, dated as of the Amendment Execution Date, with Ana Parker, the holder of Series D Warrants exercisable
for up to 4,500,000 shares of the Company’s common stock, $0.001 par value per share (“Common
Stock”), and another holder of Series D Warrants (such holder, together with Ms. Parker, the “Consenting
Warrant Holders”), to (i) terminate the beneficial ownership limitation provision in Section 1(f) of the
Series D Warrants; and (ii) lower the per share exercise price from $0.25 to $0.18 (the “Amendment”). In
accordance with Section 9 of the Series D Warrants, the Amendment applies to all Series D Warrants and is binding upon
all registered holders of such Series D Warrants.
In addition, under the Amendment, the Company agreed to issue
the Consenting Warrant Holders Series J Warrants exercisable in the aggregate for up to 3,545,474 shares of Common Stock at an
exercise price of $0.25, continent upon each Consenting Warrant Holder’s exercise of their respective Series D Warrant in
full. Each Series J Warrant has a term of one (1) year, and provides the holder with “piggy back” registration rights
under certain circumstances. On June 4, 2020, (i) the Consenting Warrant Holders exercised their respective Series D Warrant in
full and paid the Company the aggregate exercise price of $850,909.14; and (ii) the Company issued the Consenting Warrant Holders
4,727,273 shares of Common Stock upon the exercise of their Series D Warrants and Series J Warrants exercisable for 3,545,474 shares
of Common Stock in the aggregate.
Ms. Parker, her husband Michael Parker and their respective
affiliates (collectively, the “Parkers”), are the Company’s largest external shareholders, and the Parkers
previously participated in the Company’s 2015 and 2016 private placements, and June 2018, May 2019 and September 2019 registered
direct offerings.
The issuance and sale of the Series J Warrant and the shares
of Common Stock (the “Warrant Shares”) issuable thereunder (collectively, the “Securities”)
has not been, and will not upon issuance be, registered under the Securities Act of 1933, as amended (the “Securities
Act”), and the Securities may not be offered or sold in the United States absent registration under or exemption from
the Securities Act and any applicable state securities laws. The Securities will be issued and sold in reliance upon an exemption
from registration afforded by Section 4(a)(2) of the Securities Act based on the following facts: (A) each Consenting Warrant Holder
has represented that (i) she is an accredited investor as defined in Rule 501 promulgated under the Securities Act; (ii) she is
acquiring the Securities for investment only and not with a view towards, or for resale in connection with, the public sale or
distribution thereof in violation of applicable securities laws; (iii) she has sufficient investment experience to evaluate the
risks of the investment; and (B)(1) the Company used no advertising or general solicitation in connection with the issuance and
sale of the Securities to the Consenting Warrant Holders and (2) the Securities will be issued as restricted securities. This Current
Report on Form 8-K is not and shall not be deemed to be an offer to sell or the solicitation of an offer to buy any of the Securities.
|
(b)
|
Convertible Notes Offering
|
On June 4, 2020, Arch Therapeutics, Inc.
(the “Company”) issued Series 1 Unsecured Convertible Promissory Notes (each a “Convertible Note”
and collectively, the “Convertible Notes”) to several acrredited investors who are current stockholders of
the Company (collectively, the “Investors”) in the aggregate principal amount of $550,000. The Convertible
Notes were issued under a convertible note offering authorized by the Company’s board of directors (the “Convertible
Notes Offering”).
The Convertible Notes become due and
payable on June 30, 2023 (the “Maturity Date”) and may be prepaid, in whole or in part, at any time. The
Convertible Notes bear interest on the unpaid principal balance at a rate equal to ten percent (10.0%) (computed on the basis
of the actual number of days elapsed in a 365-day year) per annum until either (a) converted into shares of Common Stock
(such shares of Common Stock, the “Conversion Shares”); or (b) the outstanding principal and accrued
interest on the Convertible Notes is paid in full by the Company; provided, however, if the Convertible Notes are
converted or prepaid prior to the twelve month anniversary of their issuance, interest accrued with respect to such prepaid
or converted portion of the Convertible Note will equal ten percent (10.0%) of the principal that is prepaid or converted.
Interest on the Convertible Notes becomes due and payable upon their conversion or the Maturity Date and may become due and
payable upon the occurrence of an event of default under the Convertible Notes. The Convertible Notes contain customary
events of default, which include, among other things, (i) the Company’s failure to pay when due any principal or
interest payment under the Convertible Note within the specified cure period; (ii) the insolvency of the Company; or (iii)
the Company’s failure to pay other indebtedness of $100,000 or more within the specified cure period for such
breach.
The holders of the Convertible Notes have
the right to convert some or all of such Convertible Notes into the number of Conversion Shares determined by dividing (a) the
aggregate sum of the (i) principal amount of the Convertible Note to be converted; and (ii) amount of any accrued but unpaid interest
with respect to such portion of the Convertible Note to be converted (such aggregate sum, the “Note Obligations”);
and (b) the conversion price then in effect. The conversion price is $0.27 per share, and it may be reduced or increased proportionately
as a result of stock splits, stock dividends, recapitalizations, reorganizations, and similar transactions. The Convertible Notes
will also be automatically converted in the event a Change of Control (as defined in the Convertible Notes) occurs into the number
of Conversion Shares determined by dividing the Note Obligations then outstanding by the conversion price then in effect.
In addition to the preceding, the
Company shall also have the right to convert (i) all Note Obligations upon the closing of an equity financing that raises at
least $5,000,000 at a per share price of at least $0.27 into Conversion Shares at the conversion price then in effect; (ii)
some or all Note Obligations in the event the VWAP (as defined in the Convertible Notes) of the Common Stock equals or
exceeds $0.32 per share for at least fifteen (15) consecutive Trading Days (as defined in the Convertible Notes) into
Conversion Shares at the conversion price then in effect; and (iii) all outstanding Note Obligations outstanding as of the
Maturity Date into Conversion Shares at the conversion price then in effect in lieu of repaying such Note Obligations (an
“In-Kind Note Repayment”); provided, however, that in the case of an In-Kind Note Repayment, the
outstanding Note Obligations will equal the product of 1.35 and the aggregate sum of the principal amount of the Convertible
Note plus the amount of any accrued but unpaid interest with respect to such Convertible Note.
The issuance and sale of the
Convertible Notes and Conversion Shares (collectively, the “Securities”) has not been, and will not upon
issuance be, registered under the Securities Act, and the Securities may not be offered or sold in the United States absent
registration under or exemption from the Securities Act and any applicable state securities laws. The Securities were issued
and sold in reliance upon an exemption from registration afforded by Section 4(a)(2) of the Securities Act and Rule 506 of
Regulation D promulgated under the Securities Act, based on the following facts: each of the Investors has represented that
it is an accredited investor as defined in Rule 501(a) promulgated under the Securities Act, that it is acquiring the
Securities for investment only and not with a view towards, or for resale in connection with, the public sale or distribution
thereof in violation of applicable securities laws and that it has sufficient investment experience to evaluate the risks of
the investment; the Company used no advertising or general solicitation in connection with the issuance and sale of the
Securities to the Investors; the Securities will be issued as restricted securities.
The Company did not engage any
underwriter or placement agent in connection with the Amendment or Convertible Notes Offering.
The preceding description of the
Amendment,the Series J Warrant and the Convertible Notes is qualified in its entirety by reference to the copies of the form
of Amendment,form of Series J Warrant and form of Convertible Note filed herewith as Exhibit 10.1, Exhibit 10.2
and Exhibit 10.3 to this Current Report on Form 8-K, which are incorporated herein by reference.